BioSpace News Archive

STRIDE 3 Met Both Prespecified Primary Efficacy Endpoints, Ocular Discomfort Severity in the Overall ITT Population and in ITT Patients with More Severe Baseline Discomfort

The board of directors of Medtronic plc on Friday, March 6, 2020, approved the fiscal year 2020 fourth quarter cash dividend of $0.54 per ordinary share, representing an 8 percent increase over the prior year.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, reported financial results for the fourth quarter and full year ended December 31, 2019, along with a corporate update and outlook for 2020.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, provided details on five additional PoNS Treatment™ clinics that were recently authorized in the Greater Toronto Area and Southwestern Ontario.

Apttus and HighPoint, an IQVIA company, Have Partnered To Bring Digital Transformation To Tech Projects Across the Healthcare and Life Sciences Industry

At the Experimental Nuclear Magnetic Resonance Conference 2020, Bruker Corporation announces the recent delivery of the world’s first Avance™ NEO 1.2 GHz NMR system to the CERM at the University of Florence, Italy, and the first installation of an Avance NEO 1.1 GHz system at St. Jude Children’s Research Hospital in Memphis, TN.

Planned HIMSS attendees can still learn about the AI toilet—slated for 2022 release—which gathers comprehensive health data in real-time

Global Coronary Stent market report entitles an analysis of the market scenario, market consideration, and assumptions.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the presentation of positive findings from a previously reported investigational study that used thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6% (Sildenafil Cream) in healthy women.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces the approval of its Investigational New Drug (“IND”) application by the United States Food and Drug Administration (“FDA”) for eftilagimod alpha (“efti” or “IMP321”).